Effects of Pathologic Stage on the Learning Curve for Radical Prostatectomy: Evidence That Recurrence in Organ-confined Cancer is Largely Related to Inadequate Surgical Technique
Authors
Affiliations
Objectives: We previously demonstrated that there is a learning curve for open radical prostatectomy. We sought to determine whether the effects of the learning curve are modified by pathologic stage.
Methods: The study included 7765 eligible prostate cancer patients treated with open radical prostatectomy by one of 72 surgeons. Surgeon experience was coded as the total number of radical prostatectomies conducted by the surgeon prior to a patient's surgery. Multivariable regression models of survival time were used to evaluate the association between surgeon experience and biochemical recurrence, with adjustment for PSA, stage, and grade. Analyses were conducted separately for patients with organ-confined and locally advanced disease.
Results: Five-year recurrence-free probability for patients with organ-confined disease approached 100% for the most experienced surgeons. Conversely, the learning curve for patients with locally advanced disease reached a plateau at approximately 70%, suggesting that about a third of these patients cannot be cured by surgery alone.
Conclusions: Excellent rates of cancer control for patients with organ-confined disease treated by the most experienced surgeons suggest that the primary reason such patients recur is inadequate surgical technique.
Navigating Now and Next: Recent Advances and Future Horizons in Robotic Radical Prostatectomy.
Mian A, Tollefson M, Shah P, Sharma V, Mian A, Thompson R J Clin Med. 2024; 13(2).
PMID: 38256493 PMC: 10815957. DOI: 10.3390/jcm13020359.
Beckmann K, OCallaghan M, Vincent A, Moretti K, Brook N Asian J Urol. 2023; 10(4):502-511.
PMID: 38024435 PMC: 10659979. DOI: 10.1016/j.ajur.2022.02.014.
The Surgical Learning Curve for Biochemical Recurrence After Robot-assisted Radical Prostatectomy.
Bravi C, Delloglio P, Mazzone E, Moschovas M, Falagario U, Piazza P Eur Urol Oncol. 2022; 6(4):414-421.
PMID: 35850976 PMC: 10795739. DOI: 10.1016/j.euo.2022.06.010.
Bock D, Nyberg M, Lantz A, Carlsson S, Sjoberg D, Carlsson S Scand J Urol. 2022; 56(3):182-190.
PMID: 35546102 PMC: 9380413. DOI: 10.1080/21681805.2022.2070274.
Lee D, Chung B, Lee K Investig Clin Urol. 2021; 62(6):658-665.
PMID: 34387041 PMC: 8566784. DOI: 10.4111/icu.20210060.